Brief: Ocumension Therapeutics Says NDA For Ot-401 Approved By Center For Drug Evaluation Of NMPA
21/06/2022 14:59
June 21 (Reuters) - Ocumension Therapeutics 1477.HK :
* NDA FOR OT-401 APPROVED BY CENTER FOR DRUG EVALUATION OF
NMPA
* NDA FOR OT-401 APPROVED TO TREAT CHRONIC NON-INFECTIOUS
UVEITIS
AND COMMERCIALIZATION IN PRC
Source text for Eikon: ID:nHKStSXkS
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application